The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Is autologous transplant still needed in relapsed Hodgkin lymphoma?
Cathy Burton, MB BChir, MD, MRCP, FRCPath, St James’s University Hospital, Leeds, UK discusses the evolving role of autologous stem cell transplantation in relapsed/refractory Hodgkin lymphoma. With checkpoint inhibitors and brentuximab vedotin increasingly integrated into treatment pathways, Dr Burton reviews emerging evidence suggesting that selected low-risk patients may achieve excellent outcomes without consolidative transplant. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
